Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

Northern Jiangsu People's Hospital is the lead sponsor of 25 current clinical trials in our China register. 17 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Apixaban, Ciprofol and Esketamine. The most-studied condition is Splenectomy; Status.

ClinicalTrials.gov trials by status

Recruiting1768%
Not yet open520%
Active, closed312%

Trials by phase

Not applicable1560%
Observational624%
Phase 2312%
Phase 414%

Clinical trials sponsored by Northern Jiangsu People's Hospital

25 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function NCT07811687 · ClinicalTrials.gov ↗ · Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism	Observational	Recruiting	2026-08	China
Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis NCT07324785 · ClinicalTrials.gov ↗ · Diabetic Gastroparesis	Observational	Recruiting	2026-01	China
Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock NCT07383103 · ClinicalTrials.gov ↗ · Septic Shock Drugs: Fludrocortisone, Hydrocortisone	Phase 4	Recruiting	2026-03	China
A Pilot Study of the Effect of the Combination of Inhaled Nitric Oxide and Prone Position Under EIT Monitoring on Efficacy in Patients with ARDS NCT06741137 · ClinicalTrials.gov ↗ · ARDS	Not applicable	Recruiting	2024-01	China
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors NCT07337460 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	2025-11	China
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC NCT07050056 · ClinicalTrials.gov ↗ · Resectable NSCLC Drug: Tislelizumab	Phase 2	Recruiting	2025-08	China
Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients NCT07205471 · ClinicalTrials.gov ↗ · Cirrhoses, Liver, Splenectomy; Status, Partial	Not applicable	Recruiting	2025-09	China
The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients NCT05325424 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Splenectomy; Status	Not applicable	Recruiting	2022-03	China
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients NCT05325437 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension	Not applicable	Recruiting	2022-03	China
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients NCT05338294 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Splenectomy; Status	Not applicable	Recruiting	2022-03	China
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors NCT07337421 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	2025-09	China
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD NCT07461532 · ClinicalTrials.gov ↗ · Cirrhosis, Splenectomy, Portal Vein Thrombosis Drug: Apixaban	Not applicable	Recruiting	2026-04	China
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS NCT07461545 · ClinicalTrials.gov ↗ · Cirrhosis, Splenectomy, Portal Vein Thrombosis Drug: Apixaban	Not applicable	Recruiting	2026-04	China
Clinical Study on Laparoscopic Resection of Splenic Artery Aneurysm With Preservation of Spleen NCT07053605 · ClinicalTrials.gov ↗ · Splenic Artery Aneurysm, Immune Function, Hemodynamics	Not applicable	Recruiting	2025-06	China
Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection NCT07462091 · ClinicalTrials.gov ↗ · Cirrhosis, Hypersplenism, Hypertension, Portal	Not applicable	Recruiting	2026-03	China
Effect of Thread Embedding Acupuncture on Postoperative Ileus Recovery After Colorectal Cancer Surgery: A Multicenter Randomized Controlled Trial NCT07071987 · ClinicalTrials.gov ↗ · Colorectal Cancer, Postoperative Ileus, LARS - Low Anterior Resection Syndrome	Not applicable	Recruiting	2025-08	China
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection NCT05433467 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Hepatocellular Carcinoma	Not applicable	Recruiting	2022-05	China
Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up) NCT07585773 · ClinicalTrials.gov ↗ · Cirrhosis, Splenectomy; Status, Hypersplenism	Observational	Not yet open	2026-05	China
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism NCT07490405 · ClinicalTrials.gov ↗ · Liver Cirrhosis	Observational	Not yet open	2026-06	China
The Efficacy of Personalized Local Anesthetic Dosing Based on Ultrasound-Measured Nerve Cross-Sectional Area in Brachial Plexus Block: a Non-Inferiority Randomized Controlled Trial. NCT07353047 · ClinicalTrials.gov ↗ · Upper Limb Surgery	Not applicable	Not yet open	2026-02	China
Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up) NCT07588334 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension	Observational	Not yet open	2026-05	China
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up) NCT07588373 · ClinicalTrials.gov ↗ · Cirrhosis, Splenectomy; Status, Hypersplenism	Observational	Not yet open	2026-05	China
The Impact of Low-Dose Esketamine Combined With Ciprofol on the Quality of Early Postoperative Recovery Among Elderly Patients Undergoing Painless Gastroscopy NCT06617039 · ClinicalTrials.gov ↗ · Quality of Postoperative Recovery Drug: Ciprofol	Not applicable	Active, closed	2024-10	China
THRIVE Improves Early Postoperative Atelectasis in Long-Time Non-Tracheal Intubation Anesthesia for Gastrointestinal Endoscopy: a Clinical Study NCT06554678 · ClinicalTrials.gov ↗ · Early Postoperative Atelectasis	Not applicable	Active, closed	2024-02	China
Efficacy of Esketamine Combined With Different General Anesthetics on Quality of Postoperative Recovery NCT06976996 · ClinicalTrials.gov ↗ · Quality of Postoperative Recovery Drugs: Ciprofol, Esketamine, Propofol	Not applicable	Active, closed	2025-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Northern Jiangsu People's Hospital trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Apixaban2 Ciprofol2 Esketamine1 Fludrocortisone1 Hydrocortisone1 Propofol1 Tislelizumab1

Conditions in Northern Jiangsu People's Hospital trials

29 conditions

Splenectomy; Status7Cirrhosis5 Cirrhosis, Liver5Hypersplenism4Hypertension, Portal3Quality of Postoperative Recovery2Liver Cirrhosis2 Hepatocellular Carcinoma (HCC)2 Portal Hypertension2Splenectomy2Portal Vein Thrombosis2Lipid Profiles2Kidney Function Issue1HCC - Hepatocellular Carcinoma1Diabetic Gastroparesis1Septic Shock1ARDS1Resectable NSCLC1Cirrhoses, Liver1Partial1Early Postoperative Atelectasis1Upper Limb Surgery1Splenic Artery Aneurysm1Immune Function1

By trial register

Register	Trials	Recruiting
Clinical trials in China	25	17

A trial with sites in more than one country appears in each of those registers.

Questions about Northern Jiangsu People's Hospital trials

How many clinical trials does Northern Jiangsu People's Hospital sponsor?

Northern Jiangsu People's Hospital is the lead sponsor of 25 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Northern Jiangsu People's Hospital trials recruiting?

Yes. 17 of its 25 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Northern Jiangsu People's Hospital testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Apixaban (2), Ciprofol (2), Esketamine (1), Fludrocortisone (1) and Hydrocortisone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Northern Jiangsu People's Hospital clinical trials